Latest news
Loading news…
Igalphan
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 HighHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 High growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Tokyo, Japan Founded 2022 For Profit
Igalphan is a Japanese biotech company developing oral IgA antibody drugs targeting gut microbiota dysbiosis.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
1
Monthly Visits
Available in Pro Contacts
0
Patents
0
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 29
- Patents granted
- 0
- Trademarks
- 0
- Top patent class
- Organic Chemistry
Company Info
- Founded
- 2022
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- HQ
- Tokyo, Japan
- Region
- Asia-Pacific (APAC)
Signals & Scores
- Heat score
- High
- Growth score
- High
- Trend (7d)
- -0.1
- Trend (30d)
- 9.2
- Trend (90d)
- 9.3
Acquisitions by Igalphan
Loading columns…
0 of 0Show
Page 1 / 1
Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Igalphan
Loading news…
FAQs about Igalphan
People who checked this page also checked these
Browse the full Acquirezy directory.